A medicinal chemistry perspective on structure-based drug design and development

Methods in Molecular Biology

Volumn 841, Issue , 2012, Pages 351-381

  Maddaford, Shawn P ^a  

^a NeurAxon Inc   (Canada)

Author keywords

Drug like properties; Lead optimization; Lipophilicity; Multi parameter optimization; Structure based drug design

Indexed keywords

DRUG; PROTEIN;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; X RAY CRYSTALLOGRAPHY;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PROTEINS;

EID: 84856504042     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-520-6_15     Document Type: Article

References (82)

1. Abou-Gharbia, M. (2009) Discovery of innovative small molecule therapeutics. J. Med. Chem . 52 , 2-9.
2. Ullman, F.; Boutellier, R. (2008) Drug discovery: are productivity metrics inhibiting motivation and creativity? Drug Disc. Today , 13 (21/22), 997-1001.
3. Prentis, R. A., Lis, Y., Walker, S.R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharm . (1988) 25 , 387-396.
4. Wahling, M. Assessing the translatability of drug projects: what needs to be scored to predict success? Nat. Rev. Drug. Disc . (2009) 8 , 541-546.
5. Pidgeon, C., Ong, S., Liu, H., Qiu, X., Pidgeon, M., Dantzig, A.H., Munroe, J., Hornback, W.J., Kasher, J.S., Glunz, L., Szczerba, T. (1995) IAM chromatography: An in vitro screen for predicting drug membrane permeability. J. Med. Chem . 38 , 590-594.
6. Lipinski,C.A., Lombardo, F., Dominy, B.W., Feeny, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. (1997) 23 , 3-25. (Pubitemid 27046991)
7. Wenlock, M.C. Rupert, P.A., Barton, P., Davis, A.M.; Leeson, P.D. (2003) A Comparison of Physicochemical Profiles of Development and Marketed Oral Drugs. J. Med. Chem . 46 , 1250-1256. (Pubitemid 36428230)
8. Morphy, R. (2006) The influence of target family and functional activityon the physicochemical properties of pre-clinical compounds. J. Med. Chem . 49 , 2969-2978.
9. Morhpy, R.; Rankovic, Z. (2006) The physicochemical challenges of designing multiple ligands. J. Med. Chem . 49 (16), 4961-70. (Pubitemid 44201054)
10. Morphy, R.; Rankovic, Z. (2009) Designing multiple ligands - medicinal chemistry strategies and challenges. Curr. Pharm. Des . 15 (6), 587-600.
11. Gleeson, M.P. (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem . 51 , 817-834. (Pubitemid 351304691)
12. Wager, T.T., Hou, X., Verhoest, P.R.; Villalobos, A. (2010) Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 1 (6), 435-449.
13. Wager, T.T., Ramalakshmi Y. Chandrasekaran, Hou, X., Troutman, M.D., Verhoest, P.R., Villalobos, V., Will, Y. (2010) Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes . ACS Chem. Neurosci. 1 (6), 420-434.
14. Hoffman, M., Monroe, D.M. (2007) Coagulation 2006: a modern view of hemostasis. Hematol. Oncol. Clin. North Am . 21 (1), 1-11. (Pubitemid 46135905)
15. Ansell, J. (2007) Factor Xa or thrombin: is factor Xa a better target? J. Thromb. Haemostasis , 5 (Suppl. 1), 60-64. (Pubitemid 46958817)
16. Galanis, T.; Thomson, L.; Palladino, M.; Merli, G.J. (2011) New oral anticoagulants. J. Thromb. Thrombolysis 31 , 310-320.
17. Liener, I.E. (1996) Trypsin inhibitors: concern for human nutrition or not? J. Nutr. 116 , 920-923.
18. Herbert, J.M.; Bernat, A.; Dol. F.; Hérault, J.P.; Crépon, B.; Lormeau, J.C. (1996) DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. JPET , 276 (3), 1030-1038. (Pubitemid 126660579)
19. Kaiser, B. (2003) DX-9065a, a direct inhibitor of factor Xa. Cardiovasc. Drug Rev. 21 , 91-104. (Pubitemid 36935488)
20. Hinder, M.; Frick, A.; Jordaan, P.; Hesse, G.; Gebauer, A.; Maas, J.; Paccaly, A. (2006) Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clin. Pharmacol. Ther. 80 (6), 691-702. (Pubitemid 44920219)
21. Cohen, M., Bhatt, D.L., Alexander, JH, Montalescot, G., Bode, C, Henry, T, Tamby, J.F., Saaiman, J, Simek, S., De Swart, J. (2007) Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation . 115 (20), 2642-2651. (Pubitemid 46791363)
22. Sinha, U. (2002) ZK-807834. Berlex. Curr. Opin. Invest. Drugs. 3 , 1736-1741.
23. Diaz-Ricart, M.; Castaner, J. (2002) ZK-807834: Anticoagulant factor Xa inhibitor. Drugs Future . 27 , 748-752. (Pubitemid 36227328)
24. Leitner, J.M.; Jilma, B.; Mayr, F.B.; Cardona, F.; Spiel, A.O.; Firbas, C.; Rathgen, K.; Stähl, H.; Schühly, U; Graefe-Mody, E.U. (2007) Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin- induced coagulation. Clin. Pharmacol. Ther. 81 , 858-866. (Pubitemid 46788296)
25. Brandstetter, H.; Kühne, A.; Bode, W.; Huber, R.; von der Saal, W.; Wirthensohn, K.; Engh, R.A. (1996) X-ray structure of active siteinhibited clotting factor Xa. Implications for drug design and substrate recognition. J. Biol. Chem . 271 , 29988-29992. (Pubitemid 26389636)
26. Young, T., Abel, R., Byungchan, K., Berne, B.J., Friesner, R.A. (2007) Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding. Proc. Natl. Acad. Sci. 104 (3), 808-813. (Pubitemid 46154692)
27. Pinto, D.J.P.; Smallheer, J.M.; Cheny, D.L.; Knabb, R.M.; Wexler, R.R. (2010) Factor Xa Inhibitors, Next-Generation Antithrombotic Agents. J. Med. Chem . 53 , 6243-6274.
28. Hogben, C.A.M., Tocco, D.J., Brodie, B.B., Schanker, L.S. (1959) On the mechanism of intestinal absorption of drugs. J. Pharmacol. Exp. Ther . 125 , 275-282.
29. Palm, K.; Luthman, K.; Ros, J.; Gråsjö, J.; Artursson, P. (1999) Effect of molecular charge on intestinal epithelial drug transport: pHdependent transport of cationic drugs. J. Pharmacol. Exp. Ther . 291 , 435-443. (Pubitemid 29503509)
30. Quan, M.L., Pruitt, J.R., Ellis, C.D., Liauw, A.Y., Galemmo, R.A., Jr., Stouten, P.F.W., Wityak, J., Knabb, R.M., Thoolen, M.J.; Wong, P.C., Wexler, R.R. (1997) Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg. Med. Chem. Lett . 7 , 2813-2818. (Pubitemid 27472834)
31. Quan, M.L., Liauw, A.Y., Ellis, C.D., Pruitt, J.R., Carini, D.J.; Bostrom, L.L., Huang, P.P., Harrison, K., Knabb, R.M., Thoolen, M.J., Wong, P.C., Wexler, R.R. (1999) Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. J. Med. Chem . 42 , 2752-2759. (Pubitemid 29370421)
32. Fevig, J.M., Pinto, D.J., Han, Q., Quan, M.L., Pruitt, J.R., Jacobson, I.C., Galemo, R.A., Wang, S., Orwat, M.J., Bostrom, L.L., Knabb, R.M., Wong, P.C., Lam, P.Y.S., Wexler, R.R. (2001) Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core. Bioorg. Med. Chem. Lett . 11 , 641-645. (Pubitemid 32187946)
33. Lam, P.Y.S., Clark, C.G., Li, R., Pinto, D.J.P., Orwat, M.J., Galemmo, R.A., Fevig, J.M., Teleha, C.A., Alexander, R.S., Smallwood, A.M., Rossi, K.A., Wright, M.R., Bai, S.A., He, K., Leuttgen, J.M., Wong, P.C., Knabb, R.M., Wexler, R.R. (2003) Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. J. Med.Chem . 46 , 4405-4418. (Pubitemid 37238744)
34. Bredt, D. S., Hwang, P. M., EGlatt, C. E., Lowenstein, C., Reed, R. R., Snyder, S. H. (1991) Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 351 , 714.
35. Stuehr, D. J. (1997) Structure-function aspects in the nitric oxide synthases. Annu. Rev. Pharmacol. Toxicol. 37 , 339.
36. Siddhanta, U., Presta, A., Fan, B., Wolan, D.D., Rousseau, D.L., Stuehr, D.J. (1998) Domain swapping in inducible nitric-oxide synthase. Electron transfer occurs between flavin and heme groups located on adjacent subunits in the dimer. J.Biol.Chem. 273 (30), 18950-8. (Pubitemid 28366284)
37. Fischmann, T. H., Hruza, A., Niu, X. D., Fossetta, J. D., Lunn, C. A.; Dolphin, E., Prongay, A. J., Reichert, P., Lundell, D. J., Narula, S.K., Weber, P. C. (1999) Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat. Struct. Biol . 6 , 233.
38. Cho, H. J., Xie, Q. W., Calaycay, J., Mumford, R. A., Swiderek, K. M., Lee, T. D., Nathan, C. (1992) Calmodulin is a subunit of nitric oxide synthase from macrophages. J. Exp. Med. 176 , 599.
39. Crane, B. R., Arvai, A. S., Gachhui, R., Wu, C., Ghosh, D. K., Getzoff, E. D., Stuehr, D. J., Tainer, J. A. (1997) The structure of nitric oxide synthase oxygenase domain and inhibitor complexes. Science. 278 , 425.
40. Crane, B. R., Arvai, A. S., Ghosh, D. K., Wu, C., Getzoff, E. D., Stuehr, D. J., Tainer. J. A. (1998) Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science . 279 , 2121.
41. Raman, C. S., Li, H., Martásek, P., Král, V., Masters, B. S., Poulos, T. L. (1998) Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell . 95 , 939.
42. Li, H., Raman, C. S., Glaser, C. B., Blasko, E., Young, T. A., Parkinson, J. F., Whitlow, M., Poulos, T. L. (1999) Crystal structures of zincfree and -bound heme domain of human inducible nitric-oxide synthase. Implications for dimer stability and comparison with endothelial nitric-oxide Synthase. J. Biol. Chem. 274 , 21276.
43. Li, H., Shimizu, H., Flinspach, M., Jamal, J., Yang, W., Xian, M., Cai, T., Wen, E. Z., Jia, Q., Wang, P. G., Poulos, T. L. (2002) The novel binding mode of N-alkyl-N -hydroxyguanidine to neuronal nitric oxide synthase provides mechanistic insights into NO biosynthesis. Biochemistry . 41 , 13868.
44. Garcin, E. D., Arvai, A. S., Rosenfeld, R. J., Kroger, M. D., Crane, B. R., Andersson, G., Andrews, G., Hamley, P. J., Mallinder, P. R., Nicholls, D. J., St-Gallay, S. A., Tinker, A. C. Gensmantel, N. P., Mete, A., Cheshire, D. R., Connolly, S., Stuehr, D. J., Aberg, A., Wallace, A. V., Tainer, J. A., Getzoff, E. D. (2008) Anchored plasticity opens doors for selective inhibitor design in nitric oxide Synthase. Nat. Chem. Biol. 4 , 700.
45. Haitao, J., Huiying, L., Martásek, P., Roman, L. J., Poulos, T. L., Silverman, R. B. (2009) Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. J. Med. Chem. , 52 , 779.
46. Erdal, E.P.; Litzinger, A.; Seo, J.; Zhu, Y.; Ji, H; Silverman, R.B. (2005) Selective neuronal nitric oxide synthase inhibitors. Curr. Top. Med. Chem . 5 , 603.
47. Ashina, M.; Lassen, L.H.; Bendtsen, L.; Jensen, R.; Olesen, J. (1999) Effect of inhibition of nitric oxide Synthase on chronic tension-type headache: a randomized crossover trial. The Lancet 353 , 287-289. (Pubitemid 29088122)
48. Flinspach, H. Li, J. Jamal, W. Yang, H. Huang, J-M. Hah, J.A. Gomez-Vidal, E. A. Litzinger, R. B. Silverman and T. L. Poulos. (2004) Structural basis for dipeptide amide isoform-selective inhibition of neuronal nitric oxide synthase. Nat. Struct. Mol. Biol. 11 (1), 54-9. (Pubitemid 38173441)
49. Raman, C.S., Li, H., Martásek, P., Southan, G., Masters, B.S., Poulos. T.L. (2001) Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. Biochemistry. 40 (45), 13448-55. (Pubitemid 33130772)
50. Xue, F.; Fang, J. Lewis, W.W.; Martásek, P. Roman, L.J. Silverman, R.B. (2010) Potent and selective neuronal nitric oxide Synthase inhibitors with improved cellular permeability. Bioorg. Med. Chem. Lett. 20 , 554-557.
51. Maddaford, S.; Ramnauth, J.; Rakhit, S., Patman, J., Annedi, S. C., Andrews, J., Dove, P., Silverman, S., Renton, P. (2008) Preparation of tetrahydroquinolines and related compounds having NOS inhibitory activity. US 20080234237 A1.
52. Zheng, G.Z., Bhatia, P., Kolasa, T., Patel, M., El Kouhen, O.F., Chang, R., Uchic, M. E., Miller, L., Baker, S., Lehto, S.G., Honore, P., Wetter, J.M., Marsh, K.C., Moreland, R.B., Brioni, J.D., Stewart, A.O. (2006) Correlation between brain/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists. Bioorg. Med. Chem. Lett . 16 , 4936-4940. (Pubitemid 44175850)
53. Finlayson, K., Witchel, H.J., McCulloch, J., Sharkey, J. (2004) Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur. J. Pharmacol . 500 (1-3), 129-42. (Pubitemid 39304003)
54. Cavalli, A., Poluzzi, E., De Ponti, F., Recanatini, M. (2002) Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of hERG K+ channel blockers. J. Med. Chem . 2002, 45 , 3844-3853. (Pubitemid 35024289)
55. Ekins, S., Crumb, W.J., Sarazan, R.D., Wikel, J.H., Wrighton, S.A. (2002) Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther . 301 (2), 427-34. (Pubitemid 34429951)
56. Pearlstein, R.A., Vaz, R.J., Kang, J., Chen, X.L., Preobrazhenskaya, M., Shchekotikhin, A.E., Korolev, A.M., Lysenkova, L.N., Miroshnikova, O.V., Hendrix,J., Rampe, D. (2003) Characterization of hERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. 13 (10),1829-35. (Pubitemid 36561175)
57. Waring, M.J., Johnstone, C.A. (2007) A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett . 17 , 1759-64.
58. Wang, M.J. (2010) Lipophilicity in drug discovery. Expert Opin. Drug Discov. 5 (3), 235-48.
59. Hagmann, W.K. (2008) The many roles of fluorine in medicinal chemistry. J. Med. Chem .51 (15), 4359-4369.
60. Hale, J.J., Mills, S.G., MacCoss, M., Finke, P.E., Cascieri, M.A., Sadowski, S., Ber, E., Chicchi, G.G., Kurtz, M., Metzger, J., Eiermann, G., Tsou, N.N., Tattersall, F.D., Rupniak, N.M., Williams, A.R., Rycroft, W., Hargreaves, R., MacIntyre, D.E. (1998) Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4- fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl) methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist . J. Med. Chem . 41 (23), 4607-14. (Pubitemid 28516459)
61. Uetrecht, J. (2007) Idiosyncratic drug reactions: current understanding. Annu. Rev. Pharmacol. Toxicol . 47 , 513-539.
62. Lin, L.S., Lanza, T.J. Jr, Jewell, J.P., Liu, P., Shah, S.K., Qi, H., Tong, X., Wang, J., Xu, S.S., Fong, T.M., Shen, C.P., Lao, J., Xiao, J.C., Shearman, L.P., Stribling, D.S., Rosko, K., Strack, A., Marsh, D.J., Feng, Y., Kumar, S., Samuel, K., Yin, W., Van der Ploeg, L.H., Goulet, M.T., Hagmann, W.K. (2006) Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1- methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy} propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J. Med.Chem . 49 (26), 7584-7. (Pubitemid 46033647)
63. Sturino, C.F., O'Neill,G., Lachance, N., Boyd, M., Berthelette, C., Labelle, M., Li, L., Roy, B., Scheigetz, J., Tsou, N., Aubin, Y., Bateman, K.P., Chauret, N., Day S.H., Lévesque, J.F., Seto, C., Silva, J.H., Trimble, L.A., Carriere, M.C., Denis, D., Greig, G., Kargman, S., Lamontagne, S., Mathieu, M.C., Sawyer, N., Slipetz, D., Abraham, W.M., Jones, T., McAuliffe, M., Piechuta, H., Nicoll-Griffith, D.A., Wang, Z., Zamboni, R., Young, R.N., Metters, K.M. (2007) Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7- fluoro-5-(methylsulfonyl)-1,2, 3,4-tetrahydrocyclopenta[ b]indol-3-yl]-acetic acid (MK-0524). J. Med. Chem . 50 (4),794-806. (Pubitemid 46332991)
64. Zanda, M. (2004) Trifluoromethyl group: an effective xenobiotic function for peptide backbone modifications. New J. Chem . 28 , 1401-1411. (Pubitemid 40070411)
65. Fedorov, R., Vasan, R., Ghosh, D.K., Schlichting, L. (2004) Structures of nitric oxide synthase isoforms complex with the inhibitor AR-R17477 suggest a rational basis for specificity and inhibitor design. Proc. Natl. Acad. Sci. 101 (16), 5892-97. (Pubitemid 38520499)
66. Russell, R.J., Haire, L.F., Stevens, D.J., Collins, P.J., Lin, Y.P., Blackburn, G.M., Hay, A.J., Gamblin, S.J., Skehel, J.J. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature . 443 (7107), 45-9. (Pubitemid 44344043)
67. Skrzypcazk-Jankun, E., Borbulevych, O.Y., Zavodsky, M.I., Baranski, M.R., Padmanabhan, K., Petricek, V., Jankun, J. (2006) Effect of crystal freezing and small-molecule binding on internal cavity size in a large protein: X-ray and docking studies of lipoxygenase at ambient and low temperature at 2.0 Å resolution. Acta Crystalogr. D Biol. Crystallogr . 62 (Pt 7), 766-75. (Pubitemid 43965902)
68. Davis, A.M., St-Gallay, S.A., Kleywegt, G.J. (2008) Limitations and lessons in the use of X-ray structural information in drug design. Drug. Disc.Today . 13 , 831-41.
69. Seo, J., Igarashi, J., Li, H., Martásek, P., Roman, L.J., Poulos, T.L., Silverman, R.B. (2007) Structure-based design and synthesis of N(omega)-nitro-L-arginine-containing peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. Displacement of the heme structural water. J. Med. Chem . 50 , 2089-99. (Pubitemid 46683062)
70. Gardner, C. R.; Walsh, C. T.; Almarsson, O. (2004) Drugs as materials: valuing physical form in drug discovery. Nat. Rev. Drug Discov . 3 (11), 926-34. (Pubitemid 39529930)
71. Maddox, J. (1988) Crystals from first principles. Nature . 335, 201.
72. Ball, P. (1996) Scandal of crystal design. Nature. 381, 20 , 648-650.
73. Lipinski, C. (2002) Poor Aqueous Solubility - an Industry Wide Problem in Drug Discovery. Am. Pharm. Rev . 5 , 82-85.
74. Bak, A.; Gore, A.; Yanez, E.; Stanton, M.; Tufekcic, S.; Syed, R.; Akrami, A.; Rose, M.; Surpaneni, S.; Bostick, T.; King, A.; Neervannan, S.; Ostovic, D.; Koparkar, A. (2008) The cocrystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. J. Pharm. Sci. 97 (9), 3942-3956.
75. Stanton, M.K., Tufekcic, S., Morgan, C., Bak, A. (2009) Drug Substance and Former Structure Property Relationships in 15 Diverse Pharmaceutical Co-Crystals Cryst. Growth Des. 9 (3), 1344-52.
76. Shan, N.; Zaworotko, M. J. (2008) The role of cocrystals in pharmaceutical science. Drug Disc. Today . 13 (9-10), 440-6.
77. Zaworotko, M.J. (2007) Molecules to Crystals, Crystals to Molecules ... and Back Again? Cryst. Growth Des. 7 (1), 4-9.
78. Cheney, M. L., Shan, N., Healey, E.R., Hanna, M., Wojtas, L., Zaworotko, M. J., Sava, V., Song, S., Sanchez-Ramos, J. R. (2010) Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine. Cryst. Growth Des. 10 , 394-405.
79. Stanton, M., Bak, A. (2008) Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals. Cryst. Growth Des . 8 (10), 3856-62.
80. Stahl, P.H.; Wermuth, C.G.; Eds. (2002) Handbook of Pharmacetuical Salts: Properties, Selection and Use; Wiley: Weinheim, Germany.
81. Childs, S. L., Chyall, L. J., Dunlap, J. T., Smolenskaya, V. N., Stahly, B. C. Stahly, G. P. (2004) Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J. Am. Chem. Soc . 126 (41), 13335-42. (Pubitemid 39382761)
82. Waring, M.J. (2010) Lipophilicity in drug discovery. Expert Opin. Drug Discov. 5 (3), 235-48.